Association between endothelial dysfunction and pulmonary function in patients with post SARS-COV-2 infection.

<bold>Introduction:</bold> Pulmonary function (PF) is used to stage and evaluate the risk of pulmonary and cardiovascular disease. Endothelial dysfunction (ED) can be regarded as a clinical syndrome, associated with an increased rate of adverse cardiovascular events. <bold>Purpose:</bold> Assess the association between ED and PF in patients with previous severe SARS-COV-2 infection. <bold>Methods:</bold> A prospective cohort study was performed on hospitalized COVID-19 patients, from June 2020 to June 2023. We included subjects >18 years older, who were hospitalized due to moderate to severe SARS-COV-2 infection. Subjects who declined to participate, or died before the follow-up visit were excluded. Endothelial function was defined as TAM/TT (Maximum Altitude Time of the Wave/Total Time of the curve) index >0.30 assessed by photoplethysmography, and pulmonary function was evaluated by spirometry. <bold>Results:</bold> 181 patients were included. <italic>Eighty percent of patients had ED.</italic> Among the comorbidities present, 41.6% with diabetes mellitus, 60% were obese and 2.8% had COPD. Respect to spirometry, subjects with ED had lower FEV1 %, PEF1 L/s and DLCO ml/min/mmHg, than subjects without ED. In the multivariate model, it was found that <italic>patients with ED had a decrease of 8.6% in FEV1% than subjects without ED</italic> (Table 1). <bold>Conclusion:</bold> In patients with post SARS-COV-2 infection, an association was found between ED and PF. <fig><object-id>erj;64/suppl_68/PA299/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>